Publicações

Updated Survival Results of the Keynote-040 Study of Pembrolizumab Vs Standard-Of-Care Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AuthID
P-00Q-NDB

Author(s)

Soulieres, D

Cohen, E

Le Tourneau, C

Dinis, J

Licitra, L

Ahn, MJ

Soria, A

Machiels, JP

Mach, N

Mehra, R

Burtness, B

Zhang, PY

Cheng, J

Swaby, R

Harrington, KJ

Tipo de Documento

Abstract

Year published

2018

Publicado

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 78, Número: 13

Conference

Annual Meeting of the American-Association-For-Cancer-Research (Aacr), Date: APR 14-18, 2018, Location: Chicago, IL, Patrocinadores: Amer Assoc Canc Res

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1158/1538-7445.am2018-ct115

Wos: WOS:000468818900106

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Updated Survival Results of the Keynote-040 Study of Pembrolizumab Vs Standard-Of-Care Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Updated Survival Results of the Keynote-040 Study of Pembrolizumab Vs Standard-Of-Care Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Links Úteis

Ajuda